can transduce biomechanical and humoral signals, which can positively modulate cardiac damage induced by acute myocardial infarction (AMI). In the clinic, bone marrow stem cell (BMSC) therapy is being increasingly utilized for AMI; however, the effects of BMSC transplantation remain to be optimized. Therefore, a novel strategy to enhance BMSC-directed myocardial repair is particularly important. The present study was performed to assess the efficacy of MRTF-A-overexpressing BMSCs in a rat model of AMI. Primary cardiomyocytes were prepared from neonatal Sprague-Dawley rats and BMSCs were isolated from male Sprague-Dawley rats (aged 8-12 weeks). Annexin V-phycoerythrin/7-actinomycin D staining was used to evaluate BMSC and cardiomyocyte survival after exposure to hydrogen peroxide in vitro. B-cell lymphoma 2 (Bcl-2) protein expression was measured by flow cytometric and western blot analyses. The effects of MRTF-A-overexpressing BMSCs in a rat model of AMI were investigated by hematoxylin and eosin staining and western blot analysis of Bcl-2 expression in myocardial tissue sections. MRTF-A enhanced the migration of BMSCs, and overexpression of MRTF-A in BMSCs prevented hydrogen peroxide-induced apoptosis in primary cardiomyocytes ex vivo. In addition, co-culture of cardiomyocytes with MRTF-A-overexpressing BMSCs inhibited hydrogen peroxide-induced apoptosis and the enhanced expression of Bcl-2. Furthermore, in vivo, enhanced cell survival was observed in the MRTF-A-modified BMSC group compared with that in the control group. These observations indicated that MRTF-A-overexpressing BMSCs have the potential to exert cardioprotective effects against hydrogen peroxide-induced injury and that treatment with MRTF-A-modified BMSCs is able to reverse cardiac dysfunction after AMI.
Introduction
Cardiovascular disease (CVD) is the leading cause of mortality globally, with the majority of patients succumbing to ischemic heart disease. Acute myocardial infarction (AMI) is associated with the risk of cardiac failure and mortality (1) (2) (3) . The mainstay of current therapies for AMI is re-perfusion of the infarcted area via thrombolysis, angioplasty or bypass-grafting. However, re-perfusion following ischemia/hypoxia induces further cardiomyocyte death (4) . Over the past decade, bone marrow stem cell (BMSC) therapy has been shown to be safe in experimental animal models and AMI patients, and it is widely accepted that BMSCs improve cardiac function (5, 6) . BMSCs have the capacity to multiply and differentiate into new blood-vessel cells or to enhance mobilization of resident cardiac stem cells, predominantly via a paracrine mechanism (7, 8) . However, the efficacy of this approach is not sufficient to achieve cardiac repair.
Several pre-clinical studies have suggested that genetic strategies can improve BMSC survival and differentiation (9, 10) . Further studies have indicated that transplantation of gene-modified stem cells may be beneficial in mediating substantial functional recovery after AMI (11, 12) . However, achieving a high rate of cell survival after transplantation into an infarcted heart remains a challenge. Thus, it is necessary to reinforce BMSCs against the damaging environment, including high levels of pro-apoptotic factors, incurred as a result of ischemia and to improve the efficacy of BMSC therapy.
Serum response factors (SRF) play an important role in the regulation of nearly every known smooth muscle-specific gene via binding to the sequence [CC(A/T) 6 GG], termed a serum response element (SRE) (13, 14) . Studies have indicated that myocardin-related transcription factor-A (MRTF-A) is abundant in tissues from newborn and adult rats, elevates SRF-driven transcription and enhances the expression of target genes (13, 15) that can contribute to cardiac and neuronal protection under various forms of stress (16, 17) .
The protective effects of MRTF-A against heart disease have been demonstrated in previous studies (18) (19) (20) . Certain studies have indicated that MRTF-A regulates myofibroblast activation and fibrosis in response to the renin-angiotensin system and post-MI remodeling (20) . Of note, normalization of activated myocardin signaling in the ventricular myocardium during the mid-stages of the development of heart failure can improve impaired ventricular function (21) . Thus, MRTF-A is likely to be a key regulator of cardiac function.
In the present study, adult rat BMSCs were genetically modified to overexpress MRTF-A with the aim of protecting cardiomyocytes against hydrogen peroxide-induced damage and enhancing their resistance to ischemic conditions following transplantation in a rat model of AMI. It was hypothesized that genetic modification of BMSCs with regard to MRTF-A protects BMSCs against the ischemic environment and improves their viability in the early post-transplantation period, thereby enhancing cardiac functional recovery after AMI. AMI model and BMSC transplantation. Animals were anesthetized with pentobarbital (50 mg/kg body weight; Roche, Basel, Switzerland). All rats underwent thoracotomy at the fifth left intercostal space, the pericardium was opened and a loose 00 braided silk suture was placed around the left anterior descending coronary artery ~1-2 mm below its origin. To facilitate the successive removal of the suture, a small silicon ring was inserted in the silk thread below the knot. The chest was then closed with a silk suture to minimize heart displacement, taking care to leave the ends of the coronary suture threads emerging from the surgical wound (11, 22) . Immediately after ligation, a 31-gauge needle was used to inject 6x10 6 MRTF-A-BMSCs [injected at six sites (23) ] into the anterior and lateral aspects of the viable myocardium bordering the infarction. Twelve AMI model rats were administered an equal volume of Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich, St. Louis, MO, USA) via the same route served as medium controls. Twelve rats were injected with the empty vector-transfected BMSCs. Animals were sacrificed at 1 week post-transplantation.
Materials and methods

Animals
Primary cardiomyocyte culture. The primary cardiomyocytes were prepared from newborn Sprague-Dawley rats as previously described (24) . Briefly, post-natal day-0 primary cardiomyocytes were dissociated with 0.25% pancreatic enzymes (Sigma-Aldrich) and cultured at a density of 2x10 6 /plate in 35-mm plates. The primary cardiomyocytes were cultured in 90% DMEM, 10% fetal bovine serum (FBS; Gibco-Invitrogen, Carlsbad, CA, USA) and 100 U/ml penicillin/0.1 mg/ml streptomycin (Sigma-Aldrich).
Isolation, culture and expansion of BMSCs. BMSCs were prepared according to previous methods (25, 26) . Male Sprague-Dawley rats were sacrificed by cervical dislocation, femurs and tibias were removed and carefully flushed with DMEM-low glucose (DMEM-LG; HyClone Laboratories, Inc., Logan, UT, USA) using a 0.45-mm syringe needle until the bones became pale. The released cells were discarded and the bones were dissected into fragments of 1-3 mm 3 and digested with collagenase II (0.5 mg/ml; Sigma-Alrich) for 1-2 h in a shaking incubator at 37˚C and a shaking speed of 200 rpm. The collagenase was de-activated by dilution with DMEM-LG containing 10% FBS. The digested bone fragments were also washed by centrifuging twice for 5 min at 100 x g followed by culture in a 60-mm dish (Costar, Corning Inc., Corning, NY, USA) with DMEM-LG containing 10% FBS and penicillin/ streptomycin at 37˚C in a 5% CO 2 humidified incubator. To isolate putative BMSCs, after 72 h of culture, non-adherent cells and tissue debris were removed with phosphate-buffered saline (PBS; HyClone Laboratories), and adherent cells were maintained. On reaching 70-80% confluence, these adherent cells were detached from the plate by digestion with 0.25% (wt/v) trypsin/0.02% (wt/v) EDTA (Gibco-BRL, Invitrogen Life Technologies, Carlsbad, CA, USA) for 2-3 min and the cells were re-plated. The medium was replaced every 2-3 days.
Identification of BMSCs by flow cytometric analysis.
At passage three, the cultured BMSCs were detached from the plates by trypsin-EDTA digestion. Aliquots of cells (1x10 6 ) were washed with cold PBS and re-suspended in 100 µl PBS per Eppendorf tube and stained with fluorescein isothiocyanate-conjugated anti-mouse CD45 (Becton-Dickinson, San Jose, CA, USA), phycoerythrin (PE)-conjugated anti-mouse CD34 (eBioScience, San Diego, CA, USA) and CD90 (eBioScience) antibodies at a concentration of 2 µg/ml at 4˚C for 30 min. One tube of unstained cells was prepared as a control for the staining antibodies. Data were acquired using a BD FACScalibur fluorescence activated cell sorting cytometer (BD Biosciences, San Jose, CA, USA) and analyzed using CellQuest software (BD Accuri C6 Software 1.0.264.21; BD Biosciences).
Transfection of BMSCs with lentiviral vector.
The lentiviral vector encoding MRTF-A was obtained from ShengGong (ShenGong, Shanghai, China). Briefly, BMSCs (4x10 5 cells/well) at passage three were plated in a six-well plate (Costar) 24 h prior to transfection. BMSCs were incubated with 5 µl recombinant lentivirus (1x10 8 particles/ml) for at least 24 h in minimal culture medium containing polybrene (final concentration, 8 mg/l; Sigma-Aldrich). At 24, 48, 72 and 96 h after the first infection, lentiviral transduction of BMSCs was assessed by western blot analysis. Unbound virus was removed and replaced with fresh complete medium. The cells were then incubated for a further five days prior to H 2 O 2 treatment. BMSCs were infected with 5 µl of the empty lentiviral vector (1x10 8 particles/ ml) as a control. The multiplicity of infection was 10.
Hydrogen peroxide treatment and cell viability assay. BMSCs (1.2x10 6 ) were treated with H 2 O 2 (200 µM at 37˚C for 3 h; Beyotime Institute of Biotechnology, Haimen, China) after recombinant lentiviral infection. In addition to this, the cardiomyocytes were treated with BMSCs for 2 h (BMSCs vs. cardiomyocytes is 1:1) and 50 µM H 2 O 2 were then added to the cell mixture. BMSC and cardiomyocyte apoptosis was assayed by Annexin V-PE/7-actinomycin D (7ADD) staining (BD-559763; BD Biosciences) and analyzed by flow cytometry.
Histopathology. Ηematoxylin and eosin (H&E) staining was adopted to examine the histological alterations in the heart tissue. Briefly, the heart tissues preserved in 4% paraformaldehyde were dehydrated using Carnoy's fluid and then used to prepare paraffin-embedded sections. After being stained with H&E (Beyotime Institute of Biotechnology), the heart histomorphology of the tree shrews was observed and photographed using an Olympus imaging system (CX31; Olympus Optical Co., Ltd, Tokyo, Japan).
Western blot analysis. Cell pellets were lysed in 0.1 ml of RIPA buffer. Total cellular proteins were extracted using a Total Protein Extraction kit (Beyotime Institute of Biotechnology), quantified using the Bicinchoninic Acid Protein assay kit (Beyotime Institute of Biotechnology), separated by 10% SDS-PAGE (Beyotime Institute of Biotechnology) and transferred onto nitrocellulose membranes (Millipore, Billerica, MA, USA) at 200 mA. The membranes were blocked with 5% skimmed milk, incubated with anti-B-cell lymphoma 2 (Bcl-2) (monoclonal; 1:2,000 dilution; cat no. sc-7382; Santa Cruz Biotechnology, Dallas, TX, USA), anti-MRTF-A (monoclonal; 1:5,000 dilution; cat no. sc-398675; Santa Cruz Biotechnology) and anti-β-actin (monoclonal; 1:5,000 dilution; cat no. sc-8432; Santa Cruz Biotechnology) antibodies, and, after washing with 0.1% Tween-20 in TBS, were incubated with horseradish-peroxidase-conjugated secondary antibodies for 1.5 h at room temperature (1:10,000; Beyotime Institute of Biotechnology). The bands were then evaluated by densitometric analysis using a Desaga Cab UVIS scanner and Desaga ProViDoc software (Desaga GmbH, Wiesloch, Germany). Enhanced chemiluminescence detection of the target protein was performed with a computerized image processing system (ImageQuant 1.19; Molecular Dynamics, Sunnyvale, CA, USA) and exposed using an X-ray film.
Statistical analyses. All values are expressed as the means ± standard deviation and analyzed by SPSS Statistical software (SPSS Statistics 22.0; SPSS Inc., Stanford, CA, USA). One-way analysis of variance with Scheffe's post-hoc test for unequal sample sizes was used to compare numeric data among the four experimental groups. Datasets consisting of two groups only were compared using the unpaired Student's t-tests. A level of P<0.05 was considered to indicate statistical significance.
Results
Identification of BMSCs and infection with lentivirus.
The adherent BMSCs at passage three exhibited a surface antigen phenotype consistent with those previously reported (27); CD90-positive and CD34-and CD45-negative. Flow cytometric analysis was employed to determine surface marker expression (Fig. 1A) . The cultured BMSCs were devoid of the BMSC-specific markers CD34 and CD45, while high expression of CD90 was observed.
BMSCs at passage three were infected with 5 µl recombinant lentivirus (1x10 8 particles/ml). At 24, 48, 72 and 96 h after the first infection, lentiviral transduction of BMSCs was confirmed by western blot analysis (Fig. 1B) . A similar protocol was used for preparing negative control BMSCs transfected with empty vector. Successfully transfected BMSCs were used for transplantation into the rat model of AMI. 
MRTF-A overexpression enhances BMSC survival.
To investigate the resistance of MRTF-A to cellular injury, BMSCs were exposed to H 2 O 2 and cell viability was evaluated by flow cytometric analysis of Annexin V-PE/7ADD staining ( Fig. 2A) . BMSCs displayed morphological changes typical of apoptosis and necrosis after H 2 O 2 -mediated cellular injury. However, the number of apoptotic and necrotic cells in the MRTF-A group (27.9±5.2%) was significantly lower compared with that in the control (52.6±6.9%; P<0.01). This indicated that MRTF-A overexpression in the lentivirus-infected BMSCs partially prevented the apoptosis induced by cellular injury. BMSCs were exposed to H 2 O 2 and Bcl-2 protein expression was analyzed by western blot analysis to elucidate whether the protective effects of MRTF-A are mediated by upregulated expression of the apoptosis-associated protein Bcl-2 (Fig. 3) . Compared with the control cells, MRTF-A-overexpressing BMSCs displayed enhanced Bcl-2 expression following treatment with H 2 O 2 (P<0.01).
MRTF-A-overexpressing BMSCs exert increased protective effects on cardiomyocyte viability in an ex vivo model of cellular injury.
To determine the protective effects of MRTF-Amodified BMSCs on cardiomyocyte viability in an ex vivo model of cellular injury, primary cardiomyocytes were co-cultured with lv (-) -BMSCs or with MRTF-A-BMSCs in six-well plates. After five days, the cardiomyocytes were exposed to hydrogen peroxide and analyzed by flow cytometry. After exposure to hydrogen peroxide, the proportion of apoptotic cells was significantly reduced in the primary cardiomyocytes co-cultured with lv (-) -BMSCs (32.75±6.21%) or MRTF-A-BMSCs (21.51±5.44%) compared with that of the primary cardiomyocytes cultured in isolation (66.83±7.58; P<0.05) (Fig. 4) .
Consistent with these results, after hydrogen peroxide exposure, the expression of the apoptosis-associated protein Bcl-2 was significantly increased in the primary cardiomyocytes co-cultured with lv (-) -BMSCs or MRTF-A-BMSCs compared with that detected in the primary cardiomyocytes cultured in isolation (P<0.01; Fig. 5) . Furthermore, the protein expression of Bcl-2 in the primary cardiomyocytes co-cultured with MRTF-A-BMSCs following hydrogen peroxide exposure was obviously increased compared with that in cardiomyocytes co-cultured with lv (-) -BMSCs (Fig. 5) .
MRTF-A-overexpressing BMSCs prevent cardiac damage after
AMI. The effect of MRTF-A overexpression on the efficacy of bone marrow stem cell-based therapy was evaluated in a rat model of AMI. Immediately after ligation of the coronary artery, 6x10 6 MRTF-A-BMSCs were injected into the infarction area. Animals were sacrificed at 1 week after cell transplantation and the extent of myocardial injury was evaluated in H&E-stained sections of myocardial tissue (Fig. 6) . While no cardiac damage was apparent in the sections from the sham group, extensive damage was detected in those from the AMI group. The damaged myocardial tissue displayed marked cardiomyocyte necrosis and a number of red cells. The damage to cardiomyocytes induced by AMI was effectively improved after transplantation of lv (-) -BMSCs or MRTF-A-BMSCs, with obviously reduced necrosis and numbers of red cells observed in the myocardial tissue sections, compared to those from the AMI group. Of note, fewer red blood cells were observed in the MRTF-A-BMSCs group compared with those in the lv (-) -BMSCs group. In addition, the expression levels of Bcl-2 protein in myocardial tissues after AMI following transplantation of lv (-) -BMSCs or MRTF-A-BMSCs were assessed. Bcl-2 expression in the AMI group was significantly decreased compared with that in the sham group (P<0.01), while the levels of Bcl-2 protein in the lv (-) -BMSC and MRTF-A-BMSC groups were significantly increased compared with those in the AMI group (P<0.01) (Fig. 7) . In addition, the expression of Bcl-2 after MRTF-A-BMSC transplantation was significantly greater than that after lv (-) -BMSC transplantation.
Discussion
Although it is promising to use BMSCs in cell-based therapy (CBT) for AMI, BMSC survival is poor following trans- plantation into the heart following AMI. This may limit the functional improvements associated with this approach (28) and therefore, strategies to enhance BMSC survival are critically required for the clinical translation of this CBT.
MRTF-A, as a co-factor of SRF that is required for gene expression, has been implicated in myocardial survival (20) . The present study investigated the ability of BMSC transplantation alone and in combination with and MRTF-A overexpression to suppress cardiomyocyte injury induced by hypoxia-ischemia.
Initially, the BMSCs were isolated from male SpragueDawley rats and were subsequently cultured and expanded. Immunophenotyping analysis of BMSC surface markers revealed that these cells exhibited a surface antigen phenotype consistent with those reported previously (CD90-positive; CD34-and CD45-negative) (27) . One of the significant challenges in the clinical application of BMSC-based therapy is the low survival of transplanted cells in vivo, particularly in the heart following AMI (29) . The results of the present study showed that overexpression of MRTF-A in BMSCs partially prevented hydrogen peroxide-induced apoptosis in primary cardiomyocytes ex vivo and enhanced Bcl-2 expression in BMSCs, suggesting that MRTF-A may enhance the survival of BMSCs.
The modulation of apoptosis-associated gene expression by MRTF-A may be involved in the enhanced survival and protective effects of MRTF-A-BMSCs on cardiomyocytes. Upregulation of Bcl-2 had an important role in mediating the beneficial effects of CBT with MRTF-A-BMSCs. Western blot analysis showed that Bcl-2 was upregulated in MRTF-A-modified BMSCs. Furthermore, H 2 O 2 -induced apoptosis was ameliorated in primary cardiomyocytes co-cultured with MRTF-A-modified BMSCs, indicating that the apoptosis-associated pathways were partially inhibited by the reduction of Bcl-2 expression.
Further experiments showed that transplantation of MRTF-A-BMSCs markedly improved these parameters, indicating that MRTF-A enhances the efficacy of CBT with BMSCs. Lentivirus-mediated transduction and stable expression of MRTF-A in BMSCs improved the efficiency of CBT, demonstrating that the effect of MRTF-A is independent of lentiviral transduction. Thus, the results of the present study suggested that ex vivo modification of BMSCs with signaling molecules, such as MRTF-A, can improve their therapeutic potential in CBT.
In the present study, the effect of MRTF-A regarding the extension of the survival of grafted BMSCs under ischemia was identified in vitro and in vivo. It was confirmed that overexpression of MRTF-A reduced BMSC death and apoptosis induced by hydrogen peroxide exposure. Furthermore, in vivo transplantation of MRTF-A-BMSCs enhanced the survival of myocardial tissue in a rat model of AMI. These observations suggested that overexpression of MRTF-A in BMSCs may be of significant value in improving the efficacy of stem cell therapy following a broad range of cardiac diseases.
